2nd Clinical Trials Phase I & Phase IIA

The early phases of a clinical trial are the most crucial. This is where the potential of a drug is evaluated and applied to the treatment at stake. However, they are also the most expensive and regulated portions of a trial. It can cost up to two billion dollars just to complete these early phases of a clinical trial, and sometimes, they are even bypassed. If this does not occur, and a drug does go through Phase I and Phase IIA, corners can be proactively cut in order to decrease costs, meet regulatory requirements and ensure efficacy.

The 2nd Clinical Trials Phase I and Phase IIA Summit will explore paramount strategies behind increasing efficiency in early phase clinical trials. As the early clinical development space is continuously evolving, this must-attend event will feature countless case studies and networking opportunities to address current challenges. In addition to hearing about pharmacokinetic, pharmacogenomic and pharmacovigilant methodologies, this conference will provide the audience with the opportunity to hear from top industry thought leaders in regards to driving success into their clinical trials.

Booking: http://atnd.it/20825-1

Price:
Conference Only - Early Bird Price prior to Mar. 27, 2015: USD 1895
Conference Only - Standard Price after March 27, 2015 : USD 2095

Speakers: Matt Anderson, Merck, Tatiana Beletskaya, ARENSIA Exploratory Medicine, Larry Blankstein, Genzyme, Jesse Cedarbaum, Biogen Idec, Tami Crumley, Merck, Mark Day, Alexion Phamaceuticals, Stephen Furlong, AstraZeneca Pharmaceuticals, Larry Lesko, University of Florida, Michael Merz, Novartis, Joy Olbertz, Celerion, Jamie Oliver, Accelovance, Matt Sherman, Pfizer, Inc., Norah Shire, MedImmune, LLC, Alessandra Tosolini, Merck

Time: 8:00 am - 5:00 pm